If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,548.00    -6.00 (-0.39%)
Bid:
1,544.00
Ask:
1,547.00
Spread: 3.00 (0.194%)
Market Cap: £3.26b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Director/PDMR Shareholding

15 Mar 2022 10:58

RNS Number : 8299E
Hikma Pharmaceuticals Plc
15 March 2022
 

 

Hikma Pharmaceuticals PLC - EIP C Vesting

LONDON, 15 March 2022: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards which were granted on 12 March 2019 under the 2014 Executive Incentive Plan ("EIP") Element C.

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Said Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Said Darwazah

2

Reason for the notification

a)

Position/status

Executive Chairman

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on14 March 2022 under the EIP Element C. All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 38,862

d)

Aggregated information

- Volume

- Price

 

- Total

 

 

38,862

£0.00

£0.00

e)

Date of the transaction

14 March 2022

f)

Place of the transaction

London Stock Exchange (XLON)

Siggi Olafsson

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Sigurdur Olafsson

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on14 March 2022 under the EIP Element C. 16,299 Shares were sold to cover tax and the remainder were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 26,377

 

Price(s): £19.88

Volume(s): 16,299

d)

Aggregated information

- Volume

- Price

 

- Total

 

 

42,676

£19.88

£324,024.12

e)

Date of the transaction

14 March 2022

f)

Place of the transaction

London Stock Exchange (XLON)

Siggi Olafsson

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Sigurdur Olafsson

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

The Company granted the named individual above a conditional award to acquire Shares under a bespoke arrangement in respect of the first year of service only that operates on the same basis as Element C of the 2014 Executive Incentive Plan (EIP). 27,498 Shares were sold to cover tax and the remainder were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 44,502

 

Price(s): £19.88

Volume(s): 27,498

d)

Aggregated information

- Volume

- Price

 

- Total

 

 

72,000

£19.88

£546,660.24

e)

Date of the transaction

14 March 2022

f)

Place of the transaction

London Stock Exchange (XLON)

Mazen Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mazen Darwazah

2

Reason for the notification

a)

Position/status

Executive Vice Chairman

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on14 March 2022 under the EIP Element C. All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 26,514

d)

Aggregated information

- Volume

- Price

 

Total

 

 

26,514

£0.00

£0.00

e)

Date of the transaction

14 March 2022

f)

Place of the transaction

London Stock Exchange (XLON)

Riad Mishlawi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Riad Mishlawi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on14 March 2022 under the EIP Element C. All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 23,030

d)

Aggregated information

- Volume

- Price

 

- Total

 

 

23,030

£0.00

£0.00

e)

Date of the transaction

14 March 2022

f)

Place of the transaction

London Stock Exchange (XLON)

Majda Labadi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Majda Labadi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on14 March 2022 under the EIP Element C. All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 12,064

d)

Aggregated information

- Volume

- Price

 

- Total

 

 

12,064

£0.00

£0.00

e)

Date of the transaction

14 March 2022

f)

Place of the transaction

London Stock Exchange (XLON)

Bassam Kanaan

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Bassam Kanaan

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on14 March 2022 under the EIP Element C. All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 19,195

d)

Aggregated information

- Volume

- Price

 

- Total

 

 

19,195

£0.00

£0.00

e)

Date of the transaction

14 March 2022

f)

Place of the transaction

London Stock Exchange (XLON)

Khalid Nabilsi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Khalid Nabilsi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on14 March 2022 under the EIP Element C. All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 17,710

d)

Aggregated information

- Volume

- Price

 

- Total

 

 

17,710

£0.00

£0.00

e)

Date of the transaction

14 March 2022

f)

Place of the transaction

London Stock Exchange (XLON)

 

Brian Hoffmann

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Brian Hoffmann

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on14 March 2022 under the EIP Element C. 4,310 Shares were sold to cover tax and the remainder were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 6,975

 

Price(s): £19.88

Volume(s): 4,310

d)

Aggregated information

- Volume

- Price

 

- Total

 

 

11,285

£19.88

£85,682.80

e)

Date of the transaction

14 March 2022

f)

Place of the transaction

London Stock Exchange (XLON)

 

Susan Ringdal

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Susan Ringdal

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on14 March 2022 under the EIP Element C. 4,820 Shares were sold to cover tax and the remainder were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 5,383

 

Price(s): £19.88

Volume(s): 4,820

d)

Aggregated information

- Volume

- Price

 

- Total

 

 

10,203

£19.88

£95,821.60

e)

Date of the transaction

14 March 2022

f)

Place of the transaction

London Stock Exchange (XLON)

 

Henriette Nielsen

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Henriette Nielsen

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on14 March 2022 under the EIP Element C. 2,670 Shares were sold to cover tax and the remainder were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 4,320

 

Price(s): £19.88

Volume(s): 2,670

d)

Aggregated information

- Volume

- Price

 

- Total

 

 

6,990

£19.88

£53,079.60

e)

Date of the transaction

14 March 2022

f)

Place of the transaction

London Stock Exchange (XLON)

 

 

Peter SpeirsCompany Secretary, responsible for releasing this announcement+44 (0) 20 7399 2760

15 March 2022

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBGGDXRUBDGDU
Date   Source Headline
19th Dec 20253:43 pmRNSDirector/PDMR Shareholding
15th Dec 20253:59 pmRNSDirector/PDMR Shareholding
15th Dec 20257:00 amRNSHikma announces CEO change and Board appointment
11th Nov 202512:13 pmRNSHolding(s) in Company
11th Nov 202511:42 amRNSDirector/PDMR Shareholding
7th Nov 202512:56 pmRNSDirector/PDMR Shareholding
6th Nov 20257:00 amRNSNovember Trading Statement
1st Oct 202511:45 amRNSBlock listing Interim Review
23rd Sep 20251:52 pmRNSDirector/PDMR Shareholding
17th Sep 20259:16 amRNSDirector/PDMR Shareholding
22nd Aug 202512:02 pmRNSDirector/PDMR Shareholding
13th Aug 20251:51 pmRNSDirector/PDMR Shareholding
8th Aug 202512:59 pmRNSDirector/PDMR Shareholding
7th Aug 20257:00 amRNSHalf-year Report
9th Jul 20259:00 amRNSNotice of Results
7th Jul 20259:16 amRNSPublication of Offering Circular
9th Jun 20253:33 pmRNSDirector/PDMR Shareholding
5th Jun 20252:05 pmRNSDirector/PDMR Shareholding
3rd Jun 20251:02 pmRNSDirector/PDMR Shareholding
29th May 20257:00 amRNSFitch upgrades Hikma to ‘BBB’
20th May 20252:49 pmRNSDirector/PDMR Shareholding
15th May 202512:00 pmRNSMedium-term Group guidance ahead of US site visit
8th May 20254:35 pmRNSDirector/PDMR Shareholding
8th May 202510:48 amRNSS&P upgrades Hikma to ‘BBB’
8th May 20258:21 amRNSSettlement agreement for Xyrem® US lawsuits
30th Apr 20251:21 pmRNSDirector/PDMR Shareholding
24th Apr 20253:55 pmRNSResult of AGM
24th Apr 20257:00 amRNSTrading Statement
10th Apr 20252:36 pmRNSDirector/PDMR Shareholding
8th Apr 20251:47 pmRNSDirector/PDMR Shareholding
1st Apr 20259:30 amRNSBlock listing Interim Review
19th Mar 202510:10 amRNSAnnual Financial Report and Notice of AGM
4th Mar 202511:16 amRNSDirector/PDMR Shareholding
26th Feb 20257:00 amRNSFinal Results
10th Feb 20258:09 amRNSNotice of Results
23rd Dec 20249:46 amRNSDirector/PDMR Shareholding
7th Nov 20243:30 pmRNSOutcome of Audit Tender Process
7th Nov 20247:00 amRNSTrading Statement
24th Oct 20247:00 amRNS2024 Annual General Meeting Update Statement
1st Oct 20249:45 amRNSBlock listing Interim Review
24th Sep 202410:09 amRNSDirector/PDMR Shareholding
10th Sep 20247:00 amRNSHikma completes Xellia acquisition
13th Aug 20249:39 amRNSDirector/PDMR Shareholding
8th Aug 20247:00 amRNSHalf-year Report
29th Jul 20244:08 pmRNSDirector Declaration
15th Jul 20247:00 amRNSNotice of Results
1st Jul 20242:47 pmRNSTotal Voting Rights
27th Jun 20241:47 pmRNSDirector Declaration
17th Jun 20247:00 amRNSHikma acquires Xellia’s assets
5th Jun 20242:53 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.